177 related articles for article (PubMed ID: 36301191)
21. Boosting Clear Cell Renal Carcinoma-Specific Drug Discovery Using a Deep Learning Algorithm and Single-Cell Analysis.
Wang Y; Chen X; Tang N; Guo M; Ai D
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612943
[TBL] [Abstract][Full Text] [Related]
22. Predictors of Progression in a Series of 81 Adult Patients Surgically Managed for an Intracranial Hemangioblastoma: Implications for the Postoperative Follow-Up.
Garrido E; Ngoc HL; Guyotat J; Pelissou-Guyotat I; Jacquesson T; Delabar V; Manet R; Gallet C; Fenouil T; Streichenberger N; Vasiljevic A; Meyronet D; Jouanneau E; Ducray F; Dumot C; Picart T
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610939
[TBL] [Abstract][Full Text] [Related]
23. Current prospects of hereditary adrenal tumors: towards better clinical management.
Ohmoto A; Hayashi N; Takahashi S; Ueki A
Hered Cancer Clin Pract; 2024 Mar; 22(1):4. PubMed ID: 38532453
[TBL] [Abstract][Full Text] [Related]
24. Transcriptional Landscape of CUT-Class Homeobox Genes in Blastic Plasmacytoid Dendritic Cell Neoplasm.
Nagel S; Rand U; Pommerenke C; Meyer C
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474011
[TBL] [Abstract][Full Text] [Related]
25. HIF2α Promotes Cancer Metastasis through TCF7L2-Dependent Fatty Acid Synthesis in ccRCC.
Shi J; Lv Q; Miao D; Xiong Z; Wei Z; Wu S; Tan D; Wang K; Zhang X
Research (Wash D C); 2024; 7():0322. PubMed ID: 38390305
[TBL] [Abstract][Full Text] [Related]
26. Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma.
Nguyen CB; Oh E; Bahar P; Vaishampayan UN; Else T; Alva AS
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339352
[TBL] [Abstract][Full Text] [Related]
27. FOXA2 activates HIF2α expression to promote tumor progression and is regulated by the E3 ubiquitin ligase VHL in renal cell carcinoma.
Yang D; Li Q; Lu P; Wu D; Li W; Meng X; Xing M; Shangguan W; Chen B; Yang J; Zhang Z; Wang Z; Huang DCS; Zhao Q
J Biol Chem; 2024 Jan; 300(1):105535. PubMed ID: 38072043
[TBL] [Abstract][Full Text] [Related]
28. The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma.
Wang Y; Liu B; Li F; Zhang Y; Gao X; Wang Y; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1274239. PubMed ID: 37867526
[TBL] [Abstract][Full Text] [Related]
29. Murine Breast Cancer Radiosensitization Using Oxygen Microbubbles and Metformin: Vessels Are the Key.
Drzał A; Dziurman G; Hoła P; Lechowski J; Delalande A; Swakoń J; Pichon C; Elas M
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569531
[TBL] [Abstract][Full Text] [Related]
30. Von Hippel-Lindau Disease (VHL): Characteristic Lesions with Classic Imaging Findings.
Bajaj S; Gandhi D; Nayar D; Serhal A
J Kidney Cancer VHL; 2023; 10(3):23-31. PubMed ID: 37555195
[TBL] [Abstract][Full Text] [Related]
31. Pacak-Zhuang syndrome: a model providing new insights into tumor syndromes.
Rosenblum JS; Wang H; Nazari MA; Zhuang Z; Pacak K
Endocr Relat Cancer; 2023 Oct; 30(10):. PubMed ID: 37450881
[TBL] [Abstract][Full Text] [Related]
32. Chronic Obstructive Pulmonary Disease Is Associated with Worse Oncologic Outcomes in Early-Stage Resected Pancreatic and Periampullary Cancers.
Huang R; Hammelef E; Sabitsky M; Ream C; Khalilieh S; Zohar N; Lavu H; Bowne WB; Yeo CJ; Nevler A
Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371779
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia-inducible factor 2 is a key determinant of manganese excess and polycythemia in SLC30A10 deficiency.
Prajapati M; Zhang JZ; Mercadante CJ; Kowalski HL; Delaney B; Anderson JA; Guo S; Aghajan M; Bartnikas TB
bioRxiv; 2023 Feb; ():. PubMed ID: 36865210
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy.
Abou Khouzam R; Lehn JM; Mayr H; Clavien PA; Wallace MB; Ducreux M; Limani P; Chouaib S
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831579
[TBL] [Abstract][Full Text] [Related]
35. Update on the genetics of paragangliomas.
Gimenez-Roqueplo AP; Robledo M; Dahia PLM
Endocr Relat Cancer; 2023 Apr; 30(4):. PubMed ID: 36748842
[TBL] [Abstract][Full Text] [Related]
36. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.
Toledo RA; Jimenez C; Armaiz-Pena G; Arenillas C; Capdevila J; Dahia PLM
Endocr Rev; 2023 Mar; 44(2):312-322. PubMed ID: 36301191
[TBL] [Abstract][Full Text] [Related]
37. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
38. Belzutifan: A Narrative Drug Review.
Visweswaran V; Pavithran K
Curr Drug Res Rev; 2022; 14(2):88-95. PubMed ID: 35366789
[TBL] [Abstract][Full Text] [Related]
39. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Toledo RA
Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
[TBL] [Abstract][Full Text] [Related]
40. Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor.
Pelle E; Al-Toubah T; Morse B; Strosberg J
J Natl Compr Canc Netw; 2022 Dec; 20(12):1285-1287. PubMed ID: 36509068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
